Figure 3

In vivo effects of APR-246 in combination with cisplatin on p53-mutant ovarian A2780-CP20 tumors in mice. (a) Inhibition of tumor growth. APR-246 was administered as 2 h continuous i.v. infusion (400 mg/kg/day, treatment days 1–7). Cisplatin was administered as i.v. bolus injection (4 mg/kg/day, treatment days 2 and 6). The results are shown as mean±S.E.M. (n=10). Mann–Whitney U-test was used for statistical analysis of differences in tumor growth between treatment groups compared with control. *P<0.05; **P<0.01. (b) Activation of caspase-3. The treatment group had the same treatment schedule as the combination group in the in vivo efficacy study shown in (a) (3 mice per group). Tumor sections were immunohistochemically stained for active Caspase-3. Left panel: pictures are representative examples of evaluation scores; Score 1 (+): minimal amount of positive cells; Score 2 (++): moderate amount of positive cells. Right panel: Representative picture of each tumor analyzed